Ahmed Abdelaziz

1 ta ish

Value & Access, Novartis Pharma, Cairo, Egypt

1. 75eP Mutational spectrum of KRAS, TP53, BRAF, ERBB2, and POLE in GI malignancies across diverse populations

   Nikhil Ghadyalpatil, Umut Dişel, O. Zilola +15

   MaqolaChromatin Remodeling and CancerESMO Open20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.008761